OrganoBit Announcement
OrganoBit opens its basic protocol gallery
Based on popular demand, OrganoBit has open-sourced its basic protocol gallery for the public, making every protocol in this library free and accessible to all.
July 15, 2026
INDUSTRY NEWS
Organoid Technology
News Hub
Stay informed about the latest developments, breakthroughs, and market trends in organoid technology, biocomputing, and pharmaceutical innovation.
Industry Spotlight
FDA Modernization Act 2.0 Creates Massive Tailwinds for Organoid Technology
FDA's April 2025 animal testing phase-out initiative drives unprecedented demand for organoid platforms and New Approach Methodologies (NAMs), creating multi-billion dollar market opportunity as regulators make animal studies the exception rather than the norm within 3-5 years.
April 2025
FDA Commissioner Martin Makary
Company Updates
Latest from OrganoBit
Recent announcements and community updates from the OrganoBit team.
Explore the free gallery
Industry Updates
Latest developments in organoid technology and biocomputing innovation
Standards & Regulation
ISoOR Releases World's First International Organoid Biobank Standards (ISoOR-ISOB)
Global collaboration of 20+ experts from 10+ countries including Singapore, China, Australia, and across APAC delivers unified guidelines for organoid biobanking to enhance research reproducibility and accelerate clinical adoption.
November 2025
International Society of Organoid Research
Regulatory
EPA Recommits to Eliminating Mammalian Animal Testing by 2035
EPA Administrator Lee Zeldin announces commitment to eliminate mammalian animal testing by 2035, recognizing organoids as part of the New Approach Methods toolkit. Rodent population in EPA care reduced 91% in just 7 months.
January 22, 2026
EPA
Regulatory
FDA Approves First IND Using Only Organoid Efficacy Data
Historic milestone: Qureator and SillaJen achieve FDA approval for oncology drug IND application based solely on vascularized organoid efficacy data, establishing new regulatory precedent without animal proof-of-concept testing.
December 16, 2025
FDA
Regulatory
U.S. Senate Passes FDA Modernization Act 3.0 with Bipartisan Support
Senate unanimously passes legislation requiring FDA to update regulations to recognize organoids, organ-on-chip systems, and computational models as regulatory alternatives to animal testing within 12 months.
December 16, 2025
U.S. Senate
Partnership
Industry Consortium Launches Organoid COMMONS for Global Standards
Pluristyx leads establishment of Organoid COMMONS with 10 industry leaders to create standardized, regulatory-accepted organoid protocols and iPSC banks addressing reproducibility bottlenecks.
December 2, 2025
Pluristyx Inc.
Regulatory
FDA Issues Draft Guidance Reducing Non-Human Primate Testing for Monoclonal Antibodies
FDA releases guidance enabling reduction or elimination of six-month primate toxicity studies, promoting computational toxicology, organoid systems, and real-world human data as validated alternatives.
December 2, 2025
FDA
Market Report
Organoids Market Reaches $6.27B by 2030 with 23.2% CAGR Growth
Grand View Research projects explosive growth from $2.5B in 2025 to $6.27B by 2030, driven by increasing chronic disease prevalence, personalized medicine advances, and reduced reliance on animal testing.
October 2025
Grand View Research
Research Funding
NIH Establishes $87M Organoid Development Center to Replace Animal Testing
National Institutes of Health launches nation's first dedicated organoid development center at Frederick National Laboratory, using AI and robotics for standardized liver, lung, heart, and intestine organoid protocols.
September 2025
NIH
Scientific Breakthrough
Stanford Medicine Develops First Vascularized Heart and Liver Organoids
Breakthrough research creates organoids with integrated blood vessels, overcoming 3mm size limitation and enabling more mature, physiologically relevant models for disease research and drug testing.
October 2025
Stanford Medicine
Scientific Research
Building Reliable Organoid Models for Human-Relevant Drug Discovery
Comprehensive analysis of organoid model development standards and best practices for ensuring reliability and human relevance in preclinical drug discovery pipelines.
September 2025
Drug Target Review
Market Analysis
Liver Organoids Dominate Market with 23.34% Share
Market analysis reveals liver organoids leading pharmaceutical adoption due to critical role in drug metabolism testing and toxicity screening applications, with Grand View Research confirming market dominance.
October 2025
Grand View Research
Funding
Parallel Bio Raises $21M Series A for Organoid Drug Testing Platform
Cambridge biotech company secures funding led by AIX Ventures to scale Clinical Trial in a Dish technology, aiming to reduce $2B and 9 years from drug development timelines using human organoid models.
November 2025
Drug Discovery Trends